O	O	0	15	Transcriptional	Transcriptional	B-NP	JJ	O	4	NMOD	O
O	O	16	19	and	and	I-NP	CC	O	4	NMOD	O
O	O	20	39	posttranscriptional	posttranscriptional	I-NP	JJ	O	4	NMOD	O
O	O	40	50	regulation	regulation	I-NP	NN	O	0	ROOT	O
O	O	51	53	of	of	B-PP	IN	O	4	NMOD	O
T9	B-Entity	54	63	erythroid	erythroid	B-NP	JJ	B-DNA	8	NMOD	B-DNA
T9	I-Entity	64	68	gene	gene	I-NP	NN	I-DNA	8	NMOD	I-DNA
O	O	69	79	expression	expression	I-NP	NN	O	5	PMOD	O
O	O	80	82	in	in	B-PP	IN	O	4	NMOD	O
O	O	83	96	anthracycline	anthracycline	B-NP	NN	O	13	NMOD	O
O	O	96	97	-	-	B-NP	HYPH	O	13	NMOD	O
O	O	97	104	induced	induce	I-NP	VBN	O	13	NMOD	O
O	O	105	120	differentiation	differentiation	I-NP	NN	O	9	PMOD	O
O	O	121	123	of	of	B-PP	IN	O	13	NMOD	O
O	O	124	129	human	human	B-NP	JJ	B-cell_type	17	NMOD	B-cell_type
O	O	130	145	erythroleukemic	erythroleukemic	I-NP	JJ	I-cell_type	17	NMOD	I-cell_type
O	O	146	151	cells	cell	I-NP	NNS	I-cell_type	14	PMOD	I-cell_type
O	O	151	152	.	.	O	.	O	4	P	O

O	O	154	167	Aclacinomycin	Aclacinomycin	B-NP	NN	O	6	NMOD	O
O	O	168	169	(	(	O	(	O	4	DEP	O
O	O	169	173	ACLA	ACLA	B-NP	NN	O	4	DEP	O
O	O	173	174	)	)	O	)	O	1	NMOD	O
O	O	175	178	and	and	O	CC	O	6	NMOD	O
O	O	179	190	doxorubicin	doxorubicin	B-NP	NN	O	10	SUB	O
O	O	191	192	(	(	O	(	O	9	DEP	O
O	O	192	195	DOX	DOX	B-NP	NN	O	9	DEP	O
O	O	195	196	)	)	O	)	O	6	NMOD	O
O	O	197	201	were	be	B-VP	VBD	O	0	ROOT	O
O	O	202	206	used	use	I-VP	VBN	O	10	VC	O
O	O	207	209	at	at	B-PP	IN	O	11	VMOD	O
O	O	210	218	subtoxic	subtoxic	B-NP	JJ	O	14	NMOD	O
O	O	219	233	concentrations	concentration	I-NP	NNS	O	12	PMOD	O
O	O	234	236	to	to	B-VP	TO	O	16	VMOD	O
O	O	237	243	induce	induce	I-VP	VB	O	10	VMOD	O
O	O	244	253	erythroid	erythroid	B-NP	JJ	O	18	NMOD	O
O	O	254	269	differentiation	differentiation	I-NP	NN	O	16	OBJ	O
O	O	270	272	in	in	B-PP	IN	O	16	VMOD	O
O	O	273	276	the	the	B-NP	DT	O	25	NMOD	O
O	O	277	282	human	human	I-NP	JJ	B-cell_line	25	NMOD	B-cell_line
O	O	283	291	leukemic	leukemic	I-NP	JJ	I-cell_line	25	NMOD	I-cell_line
O	O	292	296	cell	cell	I-NP	NN	I-cell_line	25	NMOD	I-cell_line
O	O	297	301	line	line	I-NP	NN	I-cell_line	25	NMOD	I-cell_line
O	O	302	306	K562	K562	I-NP	NN	I-cell_line	19	PMOD	I-cell_line
O	O	306	307	.	.	O	.	O	10	P	O

O	O	308	312	Cell	Cell	B-NP	NN	O	2	NMOD	O
O	O	313	330	hemoglobinization	hemoglobinization	I-NP	NN	O	3	SUB	O
O	O	331	334	was	be	B-VP	VBD	O	0	ROOT	O
O	O	335	346	accompanied	accompany	I-VP	VBN	O	3	VC	O
O	O	347	349	by	by	B-PP	IN	O	4	VMOD	O
O	O	350	353	the	the	B-NP	DT	O	8	NMOD	O
O	O	354	363	increased	increase	I-NP	VBN	O	8	NMOD	O
O	O	364	374	expression	expression	I-NP	NN	O	5	PMOD	O
O	O	375	377	of	of	B-PP	IN	O	8	NMOD	O
T10	B-Entity	378	383	genes	gene	B-NP	NNS	B-DNA	9	PMOD	B-DNA
O	O	384	392	encoding	encode	B-VP	VBG	O	10	NMOD	O
O	O	393	398	gamma	gamma	B-NP	SYM	B-protein	17	NMOD	B-protein
O	O	398	399	-	-	B-NP	HYPH	I-protein	17	NMOD	I-protein
O	O	399	405	globin	globin	I-NP	NN	I-protein	17	NMOD	I-protein
O	O	406	409	and	and	I-NP	CC	O	17	NMOD	O
T1	B-Protein	410	425	porphobilinogen	porphobilinogen	I-NP	NN	B-protein	17	NMOD	B-protein
T1	I-Protein	426	435	deaminase	deaminase	I-NP	NN	I-protein	23	NMOD	I-protein
O	O	436	437	(	(	O	(	O	20	DEP	O
T2	B-Protein	437	441	PBGD	PBGD	B-NP	NN	B-protein	20	DEP	B-protein
O	O	441	442	)	)	O	)	O	17	NMOD	O
O	O	442	443	,	,	O	,	O	23	P	O
O	O	444	446	an	an	B-NP	DT	O	23	NMOD	O
O	O	447	453	enzyme	enzyme	I-NP	NN	B-protein	11	OBJ	B-protein
O	O	454	456	of	of	B-PP	IN	O	23	NMOD	O
O	O	457	461	heme	heme	B-NP	NN	O	26	NMOD	O
O	O	462	471	synthesis	synthesis	I-NP	NN	O	24	PMOD	O
O	O	471	472	.	.	O	.	O	3	P	O

O	O	473	475	By	By	B-PP	IN	O	9	VMOD	O
O	O	476	481	using	use	B-VP	VBG	O	1	PMOD	O
O	O	482	485	run	run	B-NP	NN	B-protein	2	OBJ	B-protein
O	O	485	486	-	-	B-ADVP	HYPH	O	3	P	O
O	O	486	488	on	on	B-PP	IN	O	3	NMOD	O
O	O	489	495	assays	assay	B-NP	NNS	O	5	PMOD	O
O	O	495	496	,	,	O	,	O	9	P	O
O	O	497	501	ACLA	ACLA	B-NP	NN	O	9	SUB	O
O	O	502	505	was	be	B-VP	VBD	O	0	ROOT	O
O	O	506	511	shown	show	I-VP	VBN	O	9	VC	O
O	O	512	514	to	to	I-VP	TO	O	12	VMOD	O
O	O	515	521	induce	induce	I-VP	VB	O	10	VMOD	O
O	O	522	524	an	an	B-NP	DT	O	14	NMOD	O
O	O	525	536	enhancement	enhancement	I-NP	NN	O	12	OBJ	O
O	O	537	539	of	of	B-PP	IN	O	14	NMOD	O
O	O	540	543	the	the	B-NP	DT	O	17	NMOD	O
O	O	544	557	transcription	transcription	I-NP	NN	O	15	PMOD	O
O	O	558	560	of	of	B-PP	IN	O	17	NMOD	O
T11	B-Entity	561	570	erythroid	erythroid	B-NP	JJ	B-DNA	20	NMOD	B-DNA
T11	I-Entity	571	576	genes	gene	I-NP	NNS	I-DNA	18	PMOD	I-DNA
O	O	576	577	,	,	O	,	O	20	P	O
O	O	578	587	including	include	B-PP	VBG	O	20	NMOD	O
O	O	588	593	gamma	gamma	B-NP	SYM	B-protein	37	NMOD	B-protein
O	O	593	594	-	-	B-VP	HYPH	I-protein	37	NMOD	I-protein
O	O	594	600	globin	globin	B-NP	NN	I-protein	37	NMOD	I-protein
O	O	600	601	,	,	O	,	O	37	P	O
T3	B-Protein	602	606	PBGD	PBGD	B-NP	NN	B-protein	37	NMOD	B-protein
O	O	606	607	,	,	O	,	O	37	P	O
T4	B-Protein	608	622	erythropoietin	erythropoietin	B-NP	NN	B-protein	30	NMOD	B-protein
T4	I-Protein	623	631	receptor	receptor	I-NP	NN	I-protein	37	NMOD	I-protein
O	O	631	632	,	,	O	,	O	37	P	O
O	O	633	636	and	and	O	CC	O	37	NMOD	O
T5	B-Protein	637	641	GATA	GATA	B-NP	NN	B-protein	37	NMOD	B-protein
T5	I-Protein	641	642	-	-	B-NP	HYPH	I-protein	37	NMOD	I-protein
T5	I-Protein	642	643	1	1	I-NP	CD	I-protein	37	NMOD	I-protein
O	O	644	657	transcription	transcription	I-NP	NN	O	37	NMOD	O
O	O	658	664	factor	factor	I-NP	NN	O	22	PMOD	O
O	O	664	665	.	.	O	.	O	9	P	O

O	O	666	668	In	In	B-PP	IN	O	16	VMOD	O
O	O	669	677	contrast	contrast	B-NP	NN	O	1	PMOD	O
O	O	677	678	,	,	O	,	O	16	P	O
O	O	679	681	in	in	B-PP	IN	O	16	VMOD	O
O	O	682	685	DOX	DOX	B-NP	NN	B-cell_line	8	NMOD	B-cell_line
O	O	685	686	-	-	B-NP	HYPH	I-cell_line	8	NMOD	I-cell_line
O	O	686	693	treated	treat	I-NP	VBN	I-cell_line	8	NMOD	I-cell_line
O	O	694	699	cells	cell	I-NP	NNS	I-cell_line	4	PMOD	I-cell_line
O	O	699	700	,	,	O	,	O	16	P	O
O	O	701	704	the	the	B-NP	DT	O	12	NMOD	O
O	O	705	718	transcription	transcription	I-NP	NN	O	12	NMOD	O
O	O	719	723	rate	rate	I-NP	NN	O	16	SUB	O
O	O	724	726	of	of	B-PP	IN	O	12	NMOD	O
O	O	727	732	these	these	B-NP	DT	O	15	NMOD	O
T12	B-Entity	733	738	genes	gene	I-NP	NNS	B-DNA	13	PMOD	B-DNA
O	O	739	742	was	be	B-VP	VBD	O	0	ROOT	O
O	O	743	752	unchanged	unchanged	B-ADJP	JJ	O	16	PRD	O
O	O	753	755	in	in	B-PP	IN	O	17	AMOD	O
O	O	756	766	comparison	comparison	B-NP	NN	O	18	PMOD	O
O	O	767	771	with	with	B-PP	IN	O	19	NMOD	O
O	O	772	779	control	control	B-NP	NN	B-cell_type	22	NMOD	B-cell_type
O	O	780	785	cells	cell	I-NP	NNS	I-cell_type	20	PMOD	I-cell_type
O	O	785	786	.	.	O	.	O	16	P	O

O	O	787	789	In	In	B-PP	IN	O	11	VMOD	O
O	O	790	798	addition	addition	B-NP	NN	O	1	PMOD	O
O	O	798	799	,	,	O	,	O	11	P	O
O	O	800	810	inhibition	inhibition	B-NP	NN	O	11	SUB	O
O	O	811	813	of	of	B-PP	IN	O	4	NMOD	O
O	O	814	818	mRNA	mRNA	B-NP	NN	B-RNA	7	NMOD	B-RNA
O	O	819	828	synthesis	synthesis	I-NP	NN	O	5	PMOD	O
O	O	829	833	with	with	B-PP	IN	O	7	NMOD	O
O	O	834	845	actinomycin	actinomycin	B-NP	NN	O	10	NMOD	O
O	O	846	847	D	D	I-NP	NN	O	8	PMOD	O
O	O	848	857	indicated	indicate	B-VP	VBD	O	0	ROOT	O
O	O	858	862	that	that	B-SBAR	IN	O	11	VMOD	O
O	O	863	866	DOX	DOX	B-NP	NN	B-protein	14	SUB	B-protein
O	O	867	874	induced	induce	B-VP	VBD	O	12	SBAR	O
O	O	875	877	an	an	B-NP	DT	O	17	NMOD	O
O	O	878	887	increased	increase	I-NP	VBN	O	17	NMOD	O
O	O	888	897	stability	stability	I-NP	NN	O	14	OBJ	O
O	O	898	900	of	of	B-PP	IN	O	17	NMOD	O
T6	B-Protein	901	905	PBGD	PBGD	B-NP	NN	B-RNA	21	NMOD	B-RNA
O	O	906	909	and	and	I-NP	CC	I-RNA	21	NMOD	I-RNA
T7	B-Protein	910	914	GATA	GATA	I-NP	NN	I-RNA	24	NMOD	I-RNA
T7	I-Protein	914	915	-	-	B-NP	HYPH	I-RNA	24	NMOD	I-RNA
T7	I-Protein	915	916	1	1	I-NP	CD	I-RNA	24	NMOD	I-RNA
O	O	917	922	mRNAs	mRNA	I-NP	NNS	I-RNA	18	PMOD	I-RNA
O	O	922	923	,	,	O	,	O	14	P	O
O	O	924	931	whereas	whereas	O	IN	O	14	VMOD	O
O	O	932	936	ACLA	ACLA	B-NP	NN	O	28	SUB	O
O	O	937	940	did	do	B-VP	VBD	O	26	SBAR	O
O	O	941	944	not	not	I-VP	RB	O	28	VMOD	O
O	O	945	951	affect	affect	I-VP	VB	O	28	VC	O
O	O	952	955	the	the	B-NP	DT	O	34	NMOD	O
O	O	956	960	half	half	I-NP	NN	O	34	NMOD	O
O	O	960	961	-	-	I-NP	HYPH	O	34	NMOD	O
O	O	961	966	lives	life	I-NP	NNS	O	30	OBJ	O
O	O	967	969	of	of	B-PP	IN	O	34	NMOD	O
O	O	970	975	these	these	B-NP	DT	O	37	NMOD	O
O	O	976	981	mRNAs	mRNA	I-NP	NNS	B-RNA	35	PMOD	B-RNA
O	O	981	982	.	.	O	.	O	11	P	O

O	O	983	990	Because	Because	B-SBAR	IN	O	22	VMOD	O
O	O	991	994	the	the	B-NP	DT	O	3	NMOD	O
O	O	995	1003	increase	increase	I-NP	NN	O	16	SUB	O
O	O	1004	1006	in	in	B-PP	IN	O	3	NMOD	O
O	O	1007	1016	erythroid	erythroid	B-NP	JJ	B-RNA	6	NMOD	B-RNA
O	O	1017	1021	mRNA	mRNA	I-NP	NN	I-RNA	10	NMOD	I-RNA
O	O	1022	1028	steady	steady	I-NP	JJ	O	10	NMOD	O
O	O	1028	1029	-	-	I-NP	HYPH	O	10	NMOD	O
O	O	1029	1034	state	state	I-NP	NN	O	10	NMOD	O
O	O	1035	1040	level	level	I-NP	NN	O	4	PMOD	O
O	O	1041	1043	in	in	B-PP	IN	O	3	NMOD	O
O	O	1044	1057	anthracycline	anthracycline	B-NP	NN	B-cell_line	15	NMOD	B-cell_line
O	O	1057	1058	-	-	B-NP	HYPH	I-cell_line	15	NMOD	I-cell_line
O	O	1058	1065	treated	treat	I-NP	VBN	I-cell_line	15	NMOD	I-cell_line
O	O	1066	1071	cells	cell	I-NP	NNS	I-cell_line	11	PMOD	I-cell_line
O	O	1072	1075	was	be	B-VP	VBD	O	1	SBAR	O
O	O	1076	1085	inhibited	inhibit	I-VP	VBN	O	16	VC	O
O	O	1086	1088	by	by	B-PP	IN	O	17	VMOD	O
O	O	1089	1102	cycloheximide	cycloheximide	B-NP	NN	O	18	PMOD	O
O	O	1102	1103	,	,	O	,	O	22	P	O
O	O	1104	1108	this	this	B-NP	DT	O	22	SUB	O
O	O	1109	1117	suggests	suggest	B-VP	VBZ	O	0	ROOT	O
O	O	1118	1122	that	that	B-SBAR	IN	O	22	VMOD	O
O	O	1123	1138	transcriptional	transcriptional	B-NP	JJ	O	25	NMOD	O
O	O	1139	1149	activation	activation	I-NP	NN	O	33	NMOD	O
O	O	1150	1152	in	in	B-PP	IN	O	25	NMOD	O
O	O	1153	1157	ACLA	ACLA	B-NP	NN	B-cell_line	30	NMOD	B-cell_line
O	O	1157	1158	-	-	B-NP	HYPH	I-cell_line	30	NMOD	I-cell_line
O	O	1158	1165	treated	treat	I-NP	VBN	I-cell_line	30	NMOD	I-cell_line
O	O	1166	1171	cells	cell	I-NP	NNS	I-cell_line	26	PMOD	I-cell_line
O	O	1172	1175	and	and	O	CC	O	33	NMOD	O
O	O	1176	1180	mRNA	mRNA	B-NP	NN	O	33	NMOD	O
O	O	1181	1194	stabilization	stabilization	I-NP	NN	O	39	SUB	O
O	O	1195	1197	in	in	B-PP	IN	O	33	NMOD	O
O	O	1198	1201	DOX	DOX	B-NP	NN	B-cell_line	38	NMOD	B-cell_line
O	O	1201	1202	-	-	B-NP	HYPH	I-cell_line	38	NMOD	I-cell_line
O	O	1202	1209	treated	treat	I-NP	VBN	I-cell_line	38	NMOD	I-cell_line
O	O	1210	1215	cells	cell	I-NP	NNS	I-cell_line	34	PMOD	I-cell_line
O	O	1216	1220	were	be	B-VP	VBD	O	23	SBAR	O
O	O	1221	1230	dependent	dependent	B-ADJP	JJ	O	39	PRD	O
O	O	1231	1233	on	on	B-PP	IN	O	40	AMOD	O
O	O	1234	1236	de	de	B-NP	FW	O	43	AMOD	O
O	O	1237	1241	novo	novo	I-NP	FW	O	45	NMOD	O
O	O	1242	1249	protein	protein	I-NP	NN	O	45	NMOD	O
O	O	1250	1259	synthesis	synthesis	I-NP	NN	O	41	PMOD	O
O	O	1259	1260	.	.	O	.	O	22	P	O

O	O	1261	1268	Finally	Finally	B-ADVP	RB	O	8	VMOD	O
O	O	1268	1269	,	,	O	,	O	8	P	O
T8	B-Protein	1270	1274	GATA	GATA	B-NP	NN	B-protein	7	NMOD	B-protein
T8	I-Protein	1274	1275	-	-	I-NP	HYPH	I-protein	7	NMOD	I-protein
T8	I-Protein	1275	1276	1	1	I-NP	CD	I-protein	7	NMOD	I-protein
O	O	1277	1284	protein	protein	I-NP	NN	O	7	NMOD	O
O	O	1285	1290	level	level	I-NP	NN	O	8	SUB	O
O	O	1291	1294	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1295	1300	shown	show	I-VP	VBN	O	8	VC	O
O	O	1301	1303	to	to	I-VP	TO	O	11	VMOD	O
O	O	1304	1306	be	be	I-VP	VB	O	9	VMOD	O
O	O	1307	1316	increased	increase	I-VP	VBN	O	11	VC	O
O	O	1317	1319	in	in	B-PP	IN	O	12	VMOD	O
O	O	1320	1324	ACLA	ACLA	B-NP	NN	O	13	PMOD	O
O	O	1324	1325	-	-	O	HYPH	O	14	P	O
O	O	1325	1332	treated	treat	B-VP	VBN	O	14	NMOD	O
O	O	1333	1336	but	but	B-PP	CC	O	16	VMOD	O
O	O	1337	1340	not	not	B-PP	RB	O	19	PMOD	O
O	O	1341	1343	in	in	I-PP	IN	O	16	VMOD	O
O	O	1344	1347	DOX	DOX	B-NP	NN	B-cell_line	23	NMOD	B-cell_line
O	O	1347	1348	-	-	B-NP	HYPH	I-cell_line	23	NMOD	I-cell_line
O	O	1348	1355	treated	treat	I-NP	VBN	I-cell_line	23	NMOD	I-cell_line
O	O	1356	1361	cells	cell	I-NP	NNS	I-cell_line	19	PMOD	I-cell_line
O	O	1361	1362	.	.	O	.	O	8	P	O

O	O	1363	1368	These	These	B-NP	DT	O	3	NMOD	O
O	O	1369	1372	two	two	I-NP	CD	O	3	NMOD	O
O	O	1373	1387	anthracyclines	anthracycline	I-NP	NNS	O	12	SUB	O
O	O	1387	1388	,	,	O	,	O	3	P	O
O	O	1389	1397	although	although	B-SBAR	IN	O	12	VMOD	O
O	O	1398	1405	closely	closely	B-ADJP	RB	O	7	AMOD	O
O	O	1406	1413	related	related	I-ADJP	JJ	O	5	DEP	O
O	O	1414	1416	in	in	B-PP	IN	O	7	AMOD	O
O	O	1417	1422	their	their	B-NP	PRP$	O	10	NMOD	O
O	O	1423	1433	structures	structure	I-NP	NNS	O	8	PMOD	O
O	O	1433	1434	,	,	O	,	O	12	P	O
O	O	1435	1443	appeared	appear	B-VP	VBD	O	0	ROOT	O
O	O	1444	1446	to	to	I-VP	TO	O	14	VMOD	O
O	O	1447	1450	act	act	I-VP	VB	O	12	VMOD	O
O	O	1451	1453	as	as	B-PP	IN	O	14	VMOD	O
O	O	1454	1469	differentiation	differentiation	B-NP	NN	O	17	NMOD	O
O	O	1470	1478	inducers	inducer	I-NP	NNS	O	15	PMOD	O
O	O	1479	1481	by	by	B-PP	IN	O	14	VMOD	O
O	O	1482	1490	distinct	distinct	B-NP	JJ	O	20	NMOD	O
O	O	1491	1501	mechanisms	mechanism	I-NP	NNS	O	18	PMOD	O
O	O	1501	1502	.	.	O	.	O	12	P	O

O	O	1503	1509	Indeed	Indeed	B-ADVP	RB	O	6	VMOD	O
O	O	1509	1510	,	,	O	,	O	6	P	O
T13	B-Entity	1511	1520	erythroid	erythroid	B-NP	JJ	B-DNA	5	NMOD	B-DNA
T13	I-Entity	1521	1525	gene	gene	I-NP	NN	I-DNA	5	NMOD	I-DNA
O	O	1526	1536	expression	expression	I-NP	NN	O	6	SUB	O
O	O	1537	1540	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1541	1553	demonstrated	demonstrate	I-VP	VBN	O	6	VC	O
O	O	1554	1556	to	to	I-VP	TO	O	9	VMOD	O
O	O	1557	1559	be	be	I-VP	VB	O	7	VMOD	O
O	O	1560	1569	regulated	regulate	I-VP	VBN	O	9	VC	O
O	O	1570	1587	transcriptionally	transcriptionally	B-ADVP	RB	O	10	VMOD	O
O	O	1588	1590	by	by	B-PP	IN	O	10	VMOD	O
O	O	1591	1595	ACLA	ACLA	B-NP	NN	O	12	PMOD	O
O	O	1596	1599	and	and	O	CC	O	12	PMOD	O
O	O	1600	1606	mainly	mainly	B-ADVP	RB	O	17	PMOD	O
O	O	1607	1628	posttranscriptionally	posttranscriptionally	I-ADVP	RB	O	15	AMOD	O
O	O	1629	1631	by	by	B-PP	IN	O	12	PMOD	O
O	O	1632	1635	DOX	DOX	B-NP	NN	O	17	PMOD	O
O	O	1635	1636	.	.	O	.	O	6	P	O
